Esperion Therapeutics: Chardan Maintains Negative Bias, Additional Concerns Over ETC-1002 Profile - Says Optimism May Overshoot Reality Of Datasets

Loading...
Loading...
Chardan says lack of access to ETC-1002 dataset may be worse on regulatory scrutiny than expected
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...